Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ali Keshavarz, Hossam Kadry, Ahmed Alobaida & Fakhrul Ahsan. (2020) Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension. Expert Opinion on Drug Delivery 17:4, pages 439-461.
Read now
Read now
Jesús Honorato Pérez. (2017) Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review. Expert Review of Clinical Pharmacology 10:7, pages 753-762.
Read now
Read now
Steven C Pugliese & Todd M Bull. (2016) Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension. Integrated Blood Pressure Control 9, pages 1-7.
Read now
Read now
Yong Lv, Guohong Han & Daiming Fan. (2016) Portopulmonary hypertension. Scandinavian Journal of Gastroenterology 51:7, pages 795-806.
Read now
Read now
Articles from other publishers (32)
Uyioghosa Evbayiro, Thomas Delmas & Tasnim Lat. (2023) Non-traumatic Acute Subdural Hematoma in a Patient With Scleroderma Complicated by Pulmonary Arterial Hypertension: A Case Report. Cureus.
Crossref
Crossref
Raquel Paulinetti Camara, Francisco das Neves Coelho, Natália Cruz-Martins, Patrícia Marques-Alves, Graça Castro, Rui Baptista & Filipa Ferreira. (2023) Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study. International Journal of Molecular Sciences 24:7, pages 6434.
Crossref
Crossref
Helena Gauani, Thomas Baker, Zhili Li, Vladimir S. Malinin, Walter R. Perkins, Eugene J. Sullivan & David Cipolla. (2023) Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder. Pharmaceutics 15:3, pages 934.
Crossref
Crossref
Jakob Körbelin, Julius Klein, Christiane Matuszcak, Johannes Runge, Lars Harbaum, Hans Klose & Jan K. Hennigs. (2023) Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Fraz A. Ismat, Helen H. Usansky, Raul Villa, Jun Zou & Ariel Teper. (2022) Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. Advances in Therapy.
Crossref
Crossref
Nicholas S. Hill, Jeremy P. Feldman, Sandeep Sahay, Raymond L. Benza, Ioana R. Preston, David Badesch, Robert P. Frantz, Savan Patel, Ashley Galloway & Todd M. Bull. (2022) INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulmonary Circulation 12:3.
Crossref
Crossref
Ci Song, Peter Kunovszki & Amélie Beaudet. (2022) Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. Journal of Health Economics and Outcomes Research 9:1, pages 151-160.
Crossref
Crossref
Ci Song, Peter Kunovszki & Amélie Beaudet. (2022) Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. Journal of Health Economics and Outcomes Research 9:1.
Crossref
Crossref
Amalia Baroutidou, Alexandra Arvanitaki, Adam Hatzidakis, Georgia Pitsiou, Antonios Ziakas, Haralambos Karvounis & George Giannakoulas. (2022) Haemoptysis in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Insights on Pathophysiology, Diagnosis and Management. Journal of Clinical Medicine 11:3, pages 633.
Crossref
Crossref
Hans Klose, Kelly M. Chin, Ralf Ewert, Henning Gall, Joseph Parambil, David Poch, Hans-Jürgen Seyfarth, Lene N. Axelsen, Shu-Fang Hsu Schmitz, Claudia Stein & Ioana R. Preston. (2021) Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. Respiratory Research 22:1.
Crossref
Crossref
Bret BernerTomoyuki Okuda & Hak‐Kim Chan. 2021. Drug Delivery Approaches. Drug Delivery Approaches
305
332
.
Allison E. Norlander, Melissa H. Bloodworth, Shinji Toki, Jian Zhang, Weisong Zhou, Kelli Boyd, Vasiliy V. Polosukhin, Jacqueline-Yvonne Cephus, Zachary J. Ceneviva, Vivek D. Gandhi, Nowrin U. Chowdhury, Louis-Marie Charbonnier, Lisa M. Rogers, Janey Wang, David M. Aronoff, Lisa Bastarache, Dawn C. Newcomb, Talal A. Chatila & R. Stokes PeeblesJr.Jr.. (2021) Prostaglandin I2 signaling licenses Treg suppressive function and prevents pathogenic reprogramming. Journal of Clinical Investigation 131:7.
Crossref
Crossref
Adam J. Plaunt, Sadikul Islam, Tony Macaluso, Helena Gauani, Thomas Baker, Donald Chun, Veronica Viramontes, Christina Chang, Michel R. Corboz, Richard W. Chapman, Zhili Li, David C. Cipolla, Walter R. Perkins & Vladimir S. Malinin. (2021) Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences 22:2, pages 548.
Crossref
Crossref
Richard W. Chapman, Michel R. Corboz, Carlos Fernandez, Eugene Sullivan, Andy Stautberg, Adam J. Plaunt, Donna M. Konicek, Vladimir Malinin, Zhili Li, David Cipolla & Walter Perkins. (2021) Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil. ERJ Open Research 7:1, pages 00592-2020.
Crossref
Crossref
Robert Roscigno, Toby Vaughn, Stephanie Anderson, William Wargin, Thomas Hunt & Nicholas S. Hill. (2020) Pharmacokinetics and tolerability of LIQ861, a novel dry‐powder formulation of treprostinil. Pulmonary Circulation 10:4, pages 1-9.
Crossref
Crossref
Gulsev Ozen, Yasmine Amgoud, Heba Abdelazeem, Salma Mani, Chabha Benyahia, Amel Bouhadoun, Alexy Tran-Dinh, Yves Castier, Alice Guyard, Dan Longrois, Adam M. Silverstein & Xavier Norel. (2020) Downregulation of PGI2 pathway in Pulmonary Hypertension Group-III patients. Prostaglandins, Leukotrienes and Essential Fatty Acids 160, pages 102158.
Crossref
Crossref
Lucas M. Kimmig, Chuanhong Liao & Remzi Bag. (2020) Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Lung 198:1, pages 53-58.
Crossref
Crossref
Shinji Katsuragi & Tomoaki Ikeda. 2019. Maternal and Fetal Cardiovascular Disease. Maternal and Fetal Cardiovascular Disease
129
145
.
Alexander Huang & Katherine Marseu. 2019. Principles and Practice of Anesthesia for Thoracic Surgery. Principles and Practice of Anesthesia for Thoracic Surgery
561
580
.
Manuel J. Richter, Barbara Stollfuß, Alexander Roitenberg, Frank Kleinjung, Valentin Graeff , Sabine Berghaus, Christian Müller & Hossein‐Ardeschir Ghofrani. (2018) Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial. Pulmonary Circulation 8:4, pages 1-7.
Crossref
Crossref
Ketul R Chaudhary, Yupu Deng, Colin M Suen, Mohamad Taha, Thomas H Petersen, Shirley H J Mei & Duncan J Stewart. (2018) Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling. British Journal of Pharmacology 175:20, pages 3976-3989.
Crossref
Crossref
Victor Segura-Ibarra, Suhong Wu, Nida Hassan, Jose A. Moran-Guerrero, Mauro Ferrari, Ashrith Guha, Harry Karmouty-Quintana & Elvin Blanco. (2018) Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension. Frontiers in Physiology 9.
Crossref
Crossref
Andrejs PelšsNarasimhulu GandhamsettyJames R. SmithDamien MailholMattia SilviAndrew J. A. WatsonIsabel Perez-PowellSébastien PrévostNina SchützenmeisterPeter R. MooreVarinder K. Aggarwal. (2018)
Reoptimization of the Organocatalyzed Double Aldol Domino Process to a Key Enal Intermediate and Its Application to the Total Synthesis of Δ
12
-Prostaglandin J
3
. Chemistry - A European Journal 24:38, pages 9542-9545.
Crossref
Crossref
Zeming Zhang, Zheng Li, Lu Chen & Yancun Wang. (2018) The effects of inhaled NO on plasma vasoactive factor and CTnI level in rabbits with acute massive pulmonary embolism. Acta Cirurgica Brasileira 33:7, pages 577-587.
Crossref
Crossref
Taruna K. Arora, Amit K. Arora, Monika K. Sachdeva, Satyendra K. Rajput & Arun K. Sharma. (2017) Pulmonary hypertension: Molecular aspects of current therapeutic intervention and future direction. Journal of Cellular Physiology 233:5, pages 3794-3804.
Crossref
Crossref
Jingwen Xia, Li Yang, Liang Dong, Mengjie Niu, Shengli Zhang, Zhiwei Yang, Gulinuer Wumaier, Ying Li, Xiaomin Wei, Yi Gong, Ning Zhu & Shengqing Li. (2018) Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Frontiers in Pharmacology 9.
Crossref
Crossref
Allison Light, Antonia Heininger, Kathleen Wessman, Karen Frutiger & R James White. (2017) 8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain. Pain Medicine 18:12, pages 2515-2517.
Crossref
Crossref
Judy Germani, Martha Kingman, Natalie Kitterman, Traci Stewart, Melisa Wilson & Debra Zupancic. (2017) Riociguat in PAH and CTEPH: Strategies for Patient Management. Pulmonary Therapy 3:1, pages 31-43.
Crossref
Crossref
Tobias Gessler, Hossein‐Ardeschir Ghofrani, Matthias Held, Hans Klose, Hanno Leuchte, Horst Olschewski, Stephan Rosenkranz, Lueder Fels, Na Li, Dawn Ren, Andreas Kaiser, Marcus‐Hillert Schultze‐Mosgau, Bernhard Müllinger, Beate Rohde & Werner Seeger. (2017) The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulmonary Circulation 7:2, pages 505-513.
Crossref
Crossref
Harrison W. Farber & Wendy Gin-Sing. (2016) Practical considerations for therapies targeting the prostacyclin pathway. European Respiratory Review 25:142, pages 418-430.
Crossref
Crossref
Thomas Hansen, Keyvan-Karimi Galougahi, David Celermajer, Nathalie Rasko, Owen Tang, Kristen J. Bubb & Gemma Figtree. (2016) Oxidative and nitrosative signalling in pulmonary arterial hypertension — Implications for development of novel therapies. Pharmacology & Therapeutics 165, pages 50-62.
Crossref
Crossref
Irene M. Lang & Sean P. Gaine. (2015) Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. European Respiratory Review 24:138, pages 630-641.
Crossref
Crossref